Discovery of NMDA glycine site inhibitors from the chemical universe database GDB

ChemMedChem

Volumn 3, Issue 10, 2008, Pages 1520-1524

  Nguyen, Kong Thong ^a   Syed, Salahuddin ^a   Urwyler, Stephan ^b   Bertrand, Sonia ^c   Bertrand, Daniel ^c   Reymond, Jean Louis ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Computer chemistry; Inhibitors; Receptors; Virtual screening

Indexed keywords

GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL; ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; FACTUAL DATABASE; IC 50; METABOLISM; OOCYST; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; XENOPUS;

ANIMALS; BINDING SITES; DATABASES, FACTUAL; DRUG DESIGN; GLYCINE; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; OOCYSTS; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS;

EID: 54849416977     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800198     Document Type: Article

References (30)

1. K. H. Bleicher, H.-J. Böhm, K. Müller, A. I. Alanine, Nat. Mater. Nat. Rev. Drug Discovery 2003, 2, 369-378.
2. a) T. G. Smart, Curr. Opin. Neurobiol. 1997, 7, 358-367;
3. b) D. W. Choi, S. M. Rothman, Annu. Rev. Neurosci. 1990, 13, 171-182;
4. c) J. W. Olney, Annu. Rev. Pharmacol. Toxicol. 1990, 30, 47-71;
5. d) J. W. Olney, J. Labruyere, G. Wang, D. F. Wozniak, M. T. Price, M. A. Sesma, Science 1991, 254, 1515-1518;
6. e) J. A. Kemp, R. M. McKernan, Nat. Neurosci. 2002, 5, 1039-1042;
7. f) G. P. Franks, Nat. Rev. Neurosci. 2008, 9, 370-386.
8. a) T. Fink, H. Bruggesser, J.-L. Reymond, Angew. Chem. 2005, 117, 1528-1532;
9. Angew. Chem. Int. Ed. 2005, 44, 1504-1508;
10. b) T. Fink, J.-L. Reymond, J. Chem. Inf. Model. 2007, 47, 342-353.
11. H. Furukawa, E. Gouaux, EMBO J. 2003, 22, 2873-2885.
12. N. W. Kleckner, R. Dingledine, Science 1988, 241, 835-837.
13. W. F. Hood, R. P. Compton, J. B. Monahan, Neurosci. Lett. 1989, 98, 91-95.
14. G. B. Watson, T. H. Lanthorn, Neuropharmacology 1990, 29, 727-730.
15. a) Miscreen-Molinspiration Cheminformatics Virtual Screening Toolkit, 2005.03, Molinspiration Cheminformatics: Slovensky Grob, Slovak Republic, 2005;
16. b) A. Bender, H. Y. Mussa, R. C. Glen, S. Reiling, J. Chem. Inf. Comput. Sci. 2004, 44, 170;
17. c) J. Hert, P. Willett, D. J. Wilton, P. Acklin, K. Azzaoui, E. Jacoby, A. Schuffenhauer, Org. Biomol. Chem. 2004, 2, 3256-3266;
18. d) P. Japertas, R. Didziapetris, A. Petrauskas, MiniRev. Med. Chem. 2003, 8, 797- 808.
19. ChemACX Ultra, version 8.0: CambridgeSoft Corporation, Cambridge, MA (USA), 2005.
20. J. Sadowski, J. Gasteiger, Chem. Rev. 1993, 93, 2567-2581.
21. a) G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, A. J. Olson, J. Comput. Chem. 1998, 19, 1639-1662;
22. b) S. F. Sousa, P. A. Fernandes, M. J. Ramos, Proteins Struct. Funct. Gent. 2006, 65, 15-26.
23. a) G. L. Warren, C. W. Andrews, A.-M. Capelli, B. Clarke, J. LaLonde, M. H. Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M: Woolven, C. E. Peishoff, M. S. Head, J. Med. Chem. 2006, 49, 5912-5931;
24. b) P. C. D. Hawkins, A. G. Skillman, A. Nicholls, J. Med. Chem. 2007, 50, 74-82;
25. c) N. Moitessier, P. Englebienne, D. Lee, J. Lawandi, C. R. Corbeil, Br. J. Pharmacol. 2008, 153, S7-26.
26. C. I. Schneider, S. Urwyler, Biochem. Pharmacol. 1992, 43, 1693-1699.
27. D. Lagnoux, E. Delort, C. Douat-Casassus, A. Esposito, J.-L. Reymond, Chem. Eur. J. 2004, 10, 1215-1226.
28. 50 value of 20 μm in the binding assay and a positive activation signal together with glutamate in the absence of glycine in the electrophysiological assay. The data reported herein are for the product 1 from the CBz route, which is free of any trace of glycine.
29. a) G. Henderson, J. W. Johnson, P. Ascher, J. Physiol. 1990, 430, 189-212;
30. b) P. L. Wood, Life Sci.1995, 57, 301-310.